The adoptive transfer of T cells that are engineered to express chimeric antigen receptors
(CARs) has shown remarkable success in treating B cell malignancies but only limited …

T cells genetically engineered to express chimeric antigen receptors (CARs) have proven—
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …

Cancer immunotherapy by chimeric antigen receptor-modified T (CAR-T) cells has shown
exhilarative clinical efficacy for hematological malignancies. Recently two CAR-T cell based …

Chimeric antigen receptor (CAR) T cells use re-engineered cell surface receptors to
specifically bind to and lyse oncogenic cells. Two clinically approved CAR-T–cell therapies …

Genetically engineered T cells are powerful new medicines, offering hope for curative
responses in patients with cancer. Chimaeric antigen receptors (CARs) are a class of …

The term 'immunogenic cell death'(ICD) denotes an immunologically unique type of
regulated cell death that enables, rather than suppresses, T cell-driven immune responses …

Despite being empirically designed based on a simple understanding of TCR signaling, T
cells engineered with chimeric antigen receptors (CARs) have been remarkably successful …

The expression “immunogenic cell death”(ICD) refers to a functionally unique form of cell
death that facilitates (instead of suppressing) a T cell-dependent immune response specific …

Adoptive cell transfer using chimeric antigen receptors (CAR) has emerged as one of the
most promising new therapeutic modalities for patients with relapsed or refractory B-cell …

T cells react to foreign or self-antigens through T cell receptor (TCR) signaling. Several
decades of research have delineated the mechanism of TCR signal transduction and its …